
---
title: '_玻璃泡_纳米载体增强了胰腺癌联合治疗效果'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202209/15/203728eajad4bidd1c11c7.jpg'
author: 科学网
comments: false
date: Thu, 15 Sep 2022 20:41:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202209/15/203728eajad4bidd1c11c7.jpg'
---

<div>   
<p style="line-height: 3em;"><span style="font-family: "times new roman"; font-size: 24px;">“<span style="font-family: "times new roman";">玻璃泡</span>”<span style="font-family: "times new roman";">纳米载体增强了胰腺癌联合治疗效果</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="text-align:center"><a href="https://newsroom.ucla.edu/file?fid=631fc0442cfac20f4500a137" target="_self"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202209/15/203728eajad4bidd1c11c7.jpg" title alt="PANCREATIC+CANCER+CELL+1_mid.jpg" width="510" height="366" style="width: 510px; height: 366px;" referrerpolicy="no-referrer"></a><br></p><p style="text-align: center; line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Fig. 1 </span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapy" style="font-size: 18px; font-family: "times new roman";" target="_blank">A pancreatic cancer cell, protected by its ropelike barrier. Credit: iStock.com/luismolina</a><br></p><p style="text-align:center"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202209/15/203629gtmzkuiuuan1eeun.png" title alt="NANOCARRIER.png" style="text-align: center; white-space: normal; width: 550px; height: 342px;" width="550" height="342" referrerpolicy="no-referrer"></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Fig. 2 </span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">The nanocarrier's hollow glass bubble (white, at left) is packed with irinotecan (green) and is covered by lipid layers (blue) that contain the immue-boosing drug 3M-052 (orange particles in close-up image on right). Credit: CNSI/UCLA</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据美国</span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" target="_blank" style="font-size: 18px; font-family: "times new roman"; text-decoration: underline;"><span style="font-family: 宋体;">加州大学洛杉矶分校</span> <span style="font-family: 宋体; color: windowtext;">（</span><span style="color: blue;">University of California Los Angeles</span><span style="font-family: 宋体; color: windowtext;">简称</span><span style="color: windowtext;">UCLA</span><span style="font-family: 宋体; color: windowtext;">）网站</span><span style="color: windowtext;"> 2022</span><span style="font-family: 宋体; color: windowtext;">年</span><span style="color: windowtext;">9</span><span style="font-family: 宋体; color: windowtext;">月</span><span style="color: windowtext;">13</span><span style="font-family: 宋体; color: windowtext;">日报道，</span></a><span style="font-size: 18px; font-family: "times new roman";">“<span style="font-family: 宋体;">玻璃泡</span>”<span style="font-family: 宋体;">纳米载体增强了胰腺癌联合治疗的效果（‘</span></span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapy" style="font-size: 18px; font-family: "times new roman";" target="_blank">Glass bubble’ nanocarrier boosts effects of combination therapy for pancreatic cancer</a><span style="font-size: 18px; font-family: "times new roman";">）。当两种药物在一个纳米颗粒中而不是单独递送时，治疗在小鼠身上效果更好。</span><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">此研究关键要点：</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">1<span style="font-size: 18px; font-family: 宋体;">）改善药物输送（</span></span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Improving drug delivery</span></a><span style="font-size: 18px; font-family: "times new roman";">）。定制设计的纳米颗粒将药物直接输送到肿瘤，可以避免传统化疗的毒性。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">2<span style="font-size: 18px; font-family: 宋体;">）制作一种</span>“<span style="font-size: 18px; font-family: 宋体;">组合</span>”<span style="font-size: 18px; font-family: 宋体;">载体（</span></span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Crafting a ‘combo’ carrier</span></a><span style="font-size: 18px; font-family: "times new roman";">）。研究人员设计了一种创新的纳米粒子，同时配备化疗药物和免疫系统增强药物。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">3<span style="font-size: 18px; font-family: 宋体;">）两个更好（</span></span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Two are better</span></a><span style="font-size: 18px; font-family: "times new roman";">）。与单独递送药物的纳米载体相比，两种药物纳米载体在缩小胰腺肿瘤和防止转移方面明显更好。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在过去的</span>30<span style="font-size: 18px; font-family: 宋体;">年中，癌症早期发现和治疗方面的进展已帮助将总体死亡率降低了</span>30%<span style="font-size: 18px; font-family: 宋体;">以上。然而，胰腺癌仍然难以治疗。只有九分之一的人在诊断确诊后可以存活五年，部分原因是这种癌症受到帮助其抵抗治疗的生物因素的保护。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">为了扭转局面，加州大学洛杉矶分校（</span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">UCLA</span></a><span style="font-size: 18px; font-family: "times new roman";">）的研究人员开发了一种技术，该技术使用载有伊立替康（</span><a href="https://pubs.acs.org/doi/full/10.1021/acsnano.2c06300" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">irinotecan</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）和</span>3M-052<span style="font-size: 18px; font-family: 宋体;">的纳米级颗粒对胰腺肿瘤进行联合治疗。伊立替康是一种被批准为胰腺癌药物治疗方案的一部分的化疗药物，而</span>3M-052<span style="font-size: 18px; font-family: 宋体;">是一种可以增强免疫活性并帮助克服肿瘤的抵抗力研究性药物（即试验药）。相关研究于</span>2022<span style="font-size: 18px; font-family: 宋体;">年</span>8<span style="font-size: 18px; font-family: 宋体;">月</span>3<span style="font-size: 18px; font-family: 宋体;">日已经在《</span>ACS<span style="font-size: 18px; font-family: 宋体;">纳米》（</span></span><a href="https://pubs.acs.org/doi/full/10.1021/acsnano.2c06300" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">ACS Nano</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）杂志网站发表——</span>Lijia Luo, Xiang Wang, Yu-Pei Liao, Chong Hyun Chang, Andre E. Nel. Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy. </span><a href="https://pubs.acs.org/doi/full/10.1021/acsnano.2c06300" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">ACS Nano</span></a><span style="font-size: 18px; font-family: "times new roman";">, 2022, 16(8): 13168–13182. </span><a href="https://doi.org/10.1021/acsnano.2c06300" title="DOI URL" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">DOI: 10.1021/acsnano.2c06300</span></a><span style="font-size: 18px; font-family: "times new roman";">. Publication Date:August 3, 2022. </span><a href="https://pubs.acs.org/doi/full/10.1021/acsnano.2c06300" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">https://pubs.acs.org/doi/full/10.1021/acsnano.2c06300</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">在此论文中，研究小组表明，在胰腺癌小鼠模型中，同时递送的组合优于其各部分的总和。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">此文的通讯作者、</span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">UCLA</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">加州纳米系统研究所（</span> </span><a href="https://cnsi.ucla.edu/" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">California NanoSystems Institute at UCLA</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）的杰出医学教授兼研究主任安德烈</span>·<span style="font-size: 18px; font-family: 宋体;">内尔（</span>André Nel<span style="font-size: 18px; font-family: 宋体;">）说：</span>“<span style="font-size: 18px; font-family: 宋体;">在我看来，调用免疫系统将对胰腺癌提供更好的治疗结果产生重大影响，这就是我希望这项研究所能达到的效果。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">研究人员的双载纳米载体在缩小肿瘤和预防小鼠癌症转移方面比没有纳米载体的伊立替康或独立递送两种药物的纳米载体更有效。联合疗法还将更多的抗癌免疫细胞吸引到肿瘤部位，并使血液中的药物水平保持更长时间。没有证据表明有害的副作用。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">除了阻止癌细胞生长外，伊立替康还会向免疫系统的树突状细胞发出危险信号；这些反过来又会动员杀伤性</span>T<span style="font-size: 18px; font-family: 宋体;">细胞，这些细胞会移动到肿瘤部位并破坏癌细胞。但由于胰腺癌患者的树突状细胞通常功能受损，</span>3M-052<span style="font-size: 18px; font-family: 宋体;">提供了额外的帮助，帮助它们更好地在癌症部位和附近的淋巴结中汇集杀伤性</span>T<span style="font-size: 18px; font-family: 宋体;">细胞。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">癌症的联合疗法并不新鲜，但将药物包装在同一个纳米载体中已被证明是困难的。美国食品和药物管理局（</span>Food and Drug Administration<span style="font-size: 18px; font-family: 宋体;">）仅批准了一种用于化疗的双递送纳米载体。然而，在过去的七年里，安德烈</span>·<span style="font-size: 18px; font-family: 宋体;">内尔实验室开发了一种同时递送的方法，目前的研究结果进一步证明了他们的创新纳米载体设计使药物能够比单独递送更有效地协同工作。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">大多数纳米载体由脂肪物质组成的脂质分子层组成，类似于细胞膜，具有可以包装药物的空间（</span>Fig. 2<span style="font-size: 18px; font-family: 宋体;">）。使用新设备，双层脂质围绕着一个由二氧化硅制成的核心玻璃泡，其中空内部可以填充伊立替康。在一个巧妙的转折中，</span></span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">UCLA</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">博士后研究员和第一作者罗丽佳（</span>Lijia Luo<span style="font-size: 18px; font-family: 宋体;">音译）发现</span>3M-052<span style="font-size: 18px; font-family: 宋体;">分子的脂肪尾可用于将第二种药物直接整合到这些外部脂质层中。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">载体的结构设计非常小，人类头发的宽度可以容纳</span>1000<span style="font-size: 18px; font-family: 宋体;">个载体，有助于防止药物泄漏和毒性，同时该装置进入保护胰腺癌的强大绳状屏障并传播到肿瘤位点。与其它药物载体相比，玻璃气泡提供了额外的防泄漏保护，使载体能够将更多的伊立替康输送到肿瘤部位。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">图</span>2<span style="font-size: 18px; font-family: 宋体;">（</span>Fig. 2<span style="font-size: 18px; font-family: 宋体;">）显示纳米载体的空心玻璃泡（白色，左侧）填充有伊立替康（绿色），并被脂质层（蓝色）覆盖，脂质层含有免疫促进药物</span> 3M-052<span style="font-size: 18px; font-family: 宋体;">（右侧特写图像中的橙色颗粒）。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">该团队将进行进一步的临床前实验，以测试它们在大型动物模型中的治疗效果，并确认大规模制造二氧化硅纳米载体的质量控制。</span></p><p style="line-height: 2em;"><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">UCLA</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">纳米医学部的创始人和负责人、加州大学纳米技术环境影响中心（</span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapy" target="_self">University of California’s Center for Environmental Implications of Nanotechnology</a><span style="font-size: 18px; font-family: 宋体;">）的主任安德烈</span>·<span style="font-size: 18px; font-family: 宋体;">内尔教授说：</span>“<span style="font-size: 18px; font-family: 宋体;">传统上，新的突破性技术需要</span>10-20<span style="font-size: 18px; font-family: 宋体;">年才能进入市场。纳米载体已经存在了将近</span>20<span style="font-size: 18px; font-family: 宋体;">年。虽然基于脂质的纳米载体处于领先地位，但装饰有脂质层的二氧化硅基载体很有可能加快发现速度并改善癌症免疫治疗。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">该研究得到了美国国家癌症研究所</span>(</span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">National Cancer Institute</span></a><span style="font-size: 18px; font-family: "times new roman";">)<span style="font-size: 18px; font-family: 宋体;">的支持。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="https://pubs.acs.org/doi/full/10.1021/acsnano.2c06300" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="https://newsroom.ucla.edu/releases/glass-bubble-nanocarrier-boosts-combination-cancer-therapyhttps:/www.myscience.org/linkto.php?c=8a16a342da7ef45bb1cd324cea3a3a4d" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><a href="https://pubs.acs.org/doi/full/10.1021/acsnano.2c06300" style="font-size: 18px; font-family: "arial black", "avant garde";" target="_blank">Abstract</a><br></p><p style="text-align: center;"><a href="https://pubs.acs.org/doi/full/10.1021/acsnano.2c06300" target="_self"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202209/15/203942lei8alzohdijhoji.jpg" title alt="nn2c06300_0009.webp.jpg" referrerpolicy="no-referrer"></a><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Although toll-like receptor (TLR) agonists hold great promise as immune modulators for reprogramming the suppressive immune landscape in pancreatic ductal adenocarcinoma (PDAC), their use is limited by poor pharmacokinetics (PK) and off-target systemic inflammatory effects. To overcome these challenges as well as to attain drug synergy, we developed a lipid bilayer (LB)-coated mesoporous silica nanoparticle (silicasome) platform for co-delivery of the TLR7/8 agonist 3M-052 with the immunogenic chemotherapeutic agent irinotecan. This was accomplished by incorporating the C18 lipid tail of 3M-052 in the coated LB, also useful for irinotecan remote loading in the porous interior. Not only did the co-formulated carrier improve PK, but it strengthened the irinotecan-induced immunogenic cell death response by 3M-052-mediated dendritic cell activation at the tumor site as well as participating lymph nodes. The accompanying increase in CD8<sup>+</sup> T-cell infiltration along with a reduced number of regulatory T-cells was associated with tumor shrinkage and metastasis disappearance in subcutaneous and orthotopic KRAS-mediated pancreatic carcinoma tumor models. Moreover, this therapeutic outcome was accomplished without drug or nanocarrier toxicity. All considered, dual-delivery strategies that combine chemo-immunotherapy with co-formulated TLR agonists or other lipid-soluble immune modulators predict successful intervention in heterogeneous PDAC immune landscapes.</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-212210-1355495.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-212210-1355495.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1355294.html" target="_black">患有新冠肺炎的老年人患老年痴呆的风险增加50%-80%</a><br>                    <!--大赛结束-->
                                        
  
</div>
            